Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia | Journal for ImmunoTherapy of Cancer

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

PDF +
Supplementary
Material

Clinical/translational cancer immunotherapy

Original research

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia

Online download statistics by month:

Online download statistics by month: January 2022 to March 2024

	Abstract	Full	Pdf
Jan 2022	769	784	227
Feb 2022	336	341	102
Mar 2022	230	235	110
Apr 2022	181	187	85
May 2022	175	178	90
Jun 2022	236	253	97
Jul 2022	234	245	67
Aug 2022	264	268	80
Sep 2022	203	206	64
Oct 2022	228	232	53
Nov 2022	198	198	56
Dec 2022	171	171	56
Jan 2023	171	176	66
Feb 2023	166	167	47
Mar 2023	165	167	59
Apr 2023	145	146	116
May 2023	152	152	63
Jun 2023	149	150	62
Jul 2023	121	122	53
Aug 2023	141	142	58
Sep 2023	112	113	51
Oct 2023	129	131	46
Nov 2023	111	111	43
Dec 2023	92	93	36
Jan 2024	61	63	36
Feb 2024	70	71	39
Mar 2024	130	136	76
Total	5140	5238	1938